help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2005-1453
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
91/4/1566    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perraudin, V.
Right arrow Articles by Kuhn, J.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perraudin, V.
Right arrow Articles by Kuhn, J.-M.
Related Collections
Right arrow Adrenal and Hypertension
Right arrow Neuroendocrinology and Pituitary
Right arrow Cardiovascular Endocrinology
The Journal of Clinical Endocrinology & Metabolism Vol. 91, No. 4 1566-1572
Copyright © 2006 by The Endocrine Society

Evidence for a Role of Vasopressin in the Control of Aldosterone Secretion in Primary Aldosteronism: in Vitro and in Vivo Studies

Véronique Perraudin, Catherine Delarue, Hervé Lefebvre, Jean-Luc Do Rego, Hubert Vaudry and Jean-Marc Kuhn

Institut National de la Santé et de la Recherche Médicale Unité 413 (V.P., C.D., H.L., J.-L.D.R., H.V., J.-M.K.), Laboratory of Cellular and Molecular Neuroendocrinology, European Institute for Peptide Research (IFRMP 23), University of Rouen, 76821 Mont-Saint-Aignan, France; and Institut National de la Santé et de la Recherche Médicale Center for Clinical Investigation 204 (H.L., J.-M.K.), University Hospital of Rouen, 76031 Rouen, France

Address all correspondence and requests for reprints to: Dr. Hubert Vaudry, Institut National de la Santé et de la Recherche Médicale Unité 413, Laboratory of Cellular and Molecular Neuroendocrinology, European Institute for Peptide Research (Institut Fédératif de Recherche Multidisciplinaires sur les Peptides 23), University of Rouen, 76821 Mont-Saint-Aignan, France. E-mail: hubert.vaudry{at}univ-rouen.fr.

Context: Arginine vasopressin (AVP) stimulates steroid secretion from the normal human adrenal gland and some cortisol-producing adrenocortical tumors or hyperplasia through activation of the V1a receptor.

Objective: The objective of the study was to investigate in vitro and in vivo the possible involvement of AVP in the physiopathology of primary aldosteronism.

Design: The design of the study included immunohistochemical, pharmacological, and molecular studies on aldosterone-producing adenoma (APA), followed by a monocentric, crossover trial of the orally active V1a receptor antagonist, SR 49059, in a double blind, randomized, and placebo-controlled fashion.

Setting: The study was conducted at a university hospital and research laboratory.

Patients: The study population included eight untreated patients with primary aldosteronism, four with APA and four with idiopathic hyperaldosteronism.

Main Outcome Measures: Aldosterone secretion of APA cells in vitro and plasma aldosterone, renin, and ACTH were measured.

Intervention: SR 49059 (200 mg once daily) or placebo was administered during two 1-wk treatment periods separated by a 2-wk washout.

Results: We observed the occurrence of AVP-containing cells in APA tissues. Administration of AVP to perifused APA cells induced an increase in aldosterone production, which was inhibited by a specific V1a antagonist. RT-PCR analysis showed the expression of V1a receptor mRNA in most APAs studied. In APA patients, SR 49059 did not induce any effect on basal aldosterone secretion but provoked a plasma aldosterone response to orthostatism (P < 0.03) and strengthened the positive correlation between plasma aldosterone and ACTH.

Conclusions: The present study indicates that functional V1a receptors are present in APA and suggests that AVP may exert an autocrine/paracrine control of aldosterone secretion in APA tissues.




This article has been cited by other articles:


Home page
J EndocrinolHome page
P. Ye, B. Mariniello, F. Mantero, H. Shibata, and W. E Rainey
G-protein-coupled receptors in aldosterone-producing adenomas: a potential cause of hyperaldosteronism
J. Endocrinol., October 1, 2007; 195(1): 39 - 48.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
T. Aoyagi, J.-i. Birumachi, M. Hiroyama, Y. Fujiwara, A. Sanbe, J. Yamauchi, and A. Tanoue
Alteration of Glucose Homeostasis in V1a Vasopressin Receptor-Deficient Mice
Endocrinology, May 1, 2007; 148(5): 2075 - 2084.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
D Vezzosi, D Cartier, C Regnier, P Otal, A Bennet, F Parmentier, M Plantavid, A Lacroix, H Lefebvre, and P Caron
Familial adrenocorticotropin-independent macronodular adrenal hyperplasia with aberrant serotonin and vasopressin adrenal receptors
Eur. J. Endocrinol., January 1, 2007; 156(1): 21 - 31.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society